226 related articles for article (PubMed ID: 20503149)
1. Efficacy and safety of levetiracetam for outpatient alcohol detoxification.
Müller CA; Schäfer M; Schneider S; Heimann HM; Hinzpeter A; Volkmar K; Förg A; Heinz A; Hein J
Pharmacopsychiatry; 2010 Jul; 43(5):184-9. PubMed ID: 20503149
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of outpatient alcohol detoxification with a combination of tiapride/carbamazepine: additional evidence.
Soyka M; Schmidt F; Schmidt P
Pharmacopsychiatry; 2006 Jan; 39(1):30-4. PubMed ID: 16453252
[TBL] [Abstract][Full Text] [Related]
3. Outpatient alcohol detoxification: implementation efficacy and outcome effectiveness of a model project.
Soyka M; Horak M
Eur Addict Res; 2004; 10(4):180-7. PubMed ID: 15367820
[TBL] [Abstract][Full Text] [Related]
4. A combination of levetiracetam and tiapride for outpatient alcohol detoxification: a case series.
Müller CA; Schäfer M; Banas R; Heimann HM; Volkmar K; Förg A; Heinz A; Hein J
J Addict Med; 2011 Jun; 5(2):153-6. PubMed ID: 21769061
[TBL] [Abstract][Full Text] [Related]
5. A combination of carbamazepine/tiapride in outpatient alcohol detoxification. Results from an open clinical study.
Soyka M; Morhart-Klute V; Horak M
Eur Arch Psychiatry Clin Neurosci; 2002 Oct; 252(5):197-200. PubMed ID: 12451459
[TBL] [Abstract][Full Text] [Related]
6. [Short- and medium-term outcome of outpatient treatment of alcohol dependent patients. A 6-, 18- and 36-month follow-up].
Mundle G; Brügel R; Urbaniak H; Längle G; Buchkremer G; Mann K
Fortschr Neurol Psychiatr; 2001 Aug; 69(8):374-8. PubMed ID: 11584687
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of pregabalin in the treatment of alcohol withdrawal syndrome: a randomized placebo-controlled trial.
Förg A; Hein J; Volkmar K; Winter M; Richter C; Heinz A; Müller CA
Alcohol Alcohol; 2012; 47(2):149-55. PubMed ID: 22215002
[TBL] [Abstract][Full Text] [Related]
8. Outpatient alcoholism treatment: predictors of outcome after 3 years.
Bottlender M; Soyka M
Drug Alcohol Depend; 2005 Oct; 80(1):83-9. PubMed ID: 15878808
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of levetiracetam for the prevention of alcohol relapse in recently detoxified alcohol-dependent patients: a randomized trial.
Richter C; Effenberger S; Bschor T; Bonnet U; Haasen C; Preuss UW; Heinz A; Förg A; Volkmar K; Glauner T; Schaefer M
J Clin Psychopharmacol; 2012 Aug; 32(4):558-62. PubMed ID: 22722516
[TBL] [Abstract][Full Text] [Related]
10. Divalproex sodium (Depakote) for alcohol withdrawal and relapse prevention.
Longo LP; Campbell T; Hubatch S
J Addict Dis; 2002; 21(2):55-64. PubMed ID: 11916372
[TBL] [Abstract][Full Text] [Related]
11. Open label, long-term, pragmatic study on levetiracetam in the treatment of juvenile myoclonic epilepsy.
Specchio LM; Gambardella A; Giallonardo AT; Michelucci R; Specchio N; Boero G; La Neve A
Epilepsy Res; 2006 Sep; 71(1):32-9. PubMed ID: 16814521
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of levetiracetam 1000-3000 mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study.
Beran RG; Berkovic SF; Black AB; Danta G; Hiersemenzel R; Schapel GJ; Vajda FJ
Epilepsy Res; 2005 Jan; 63(1):1-9. PubMed ID: 15716083
[TBL] [Abstract][Full Text] [Related]
13. Levetiracetam: a long-term follow-up study of efficacy and safety.
Bauer J; Ben-Menachem E; Krämer G; Fryze W; Da Silva S; Kasteleijn-Nolst Trenité DG
Acta Neurol Scand; 2006 Sep; 114(3):169-76. PubMed ID: 16911344
[TBL] [Abstract][Full Text] [Related]
14. Add-on levetiracetam in children and adolescents with refractory epilepsy: results of an open-label multi-centre study.
Callenbach PM; Arts WF; ten Houten R; Augustijn P; Gunning WB; Peeters EA; Weber AM; Stroink H; Geerts Y; Geerts AT; Brouwer OF
Eur J Paediatr Neurol; 2008 Jul; 12(4):321-7. PubMed ID: 17950011
[TBL] [Abstract][Full Text] [Related]
15. Follow-up of 180 alcoholic patients for up to 7 years after outpatient treatment: impact of alcohol deterrents on outcome.
Krampe H; Stawicki S; Wagner T; Bartels C; Aust C; Rüther E; Poser W; Ehrenreich H
Alcohol Clin Exp Res; 2006 Jan; 30(1):86-95. PubMed ID: 16433735
[TBL] [Abstract][Full Text] [Related]
16. [Ambulatory detoxification of alcoholic patients--evaluation of a model project].
Soyka M; Horak M
Gesundheitswesen; 2000 Jan; 62(1):15-20. PubMed ID: 10705659
[TBL] [Abstract][Full Text] [Related]
17. Levetiracetam for the treatment of alcohol withdrawal syndrome: a multicenter, prospective, randomized, placebo-controlled trial.
Richter C; Hinzpeter A; Schmidt F; Kienast T; Preuss UW; Plenge T; Heinz A; Schaefer M
J Clin Psychopharmacol; 2010 Dec; 30(6):720-5. PubMed ID: 21105289
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of levetiracetam (3,000 mg/Day) as an adjunctive therapy in Chinese patients with refractory partial seizures.
Xiao Z; Li JM; Wang XF; Xiao F; Xi ZQ; Lv Y; Sun HB
Eur Neurol; 2009; 61(4):233-9. PubMed ID: 19176965
[TBL] [Abstract][Full Text] [Related]
19. Levetiracetam in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center.
Bootsma HP; Ricker L; Diepman L; Gehring J; Hulsman J; Lambrechts D; Leenen L; Majoie M; Schellekens A; de Krom M; Aldenkamp AP
Epilepsy Behav; 2007 Mar; 10(2):296-303. PubMed ID: 17317325
[TBL] [Abstract][Full Text] [Related]
20. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study.
Hulhoven R; Rosillon D; Bridson WE; Meeus MA; Salas E; Stockis A
Clin Ther; 2008 Feb; 30(2):260-70. PubMed ID: 18343264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
